Antonio R Pera
CIK 1689325 · President, Par Pharmaceutical · last filed 2026-06-10
Antonio R Pera is a President, Par Pharmaceutical who has filed 29 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for ANIP, was dated Jun 10, 2026. Across all open-market trades the lifetime net is −$1.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.0M across reported positions. 14 SEC filings were submitted jointly with Endo International plc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ANIP price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
104 CARNEGIE CENTER, SUITE 300
PRINCETON, NJ 08540
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ANIP | Director | 27,017 | $72.29 | $1.95M | -$1.69M | 12 | 2026-06-10 |
| Endo International plc (ENDP) Delisted | President, Par Pharmaceutical | 65,648 | $0.29 | $19.2K | $0 | 13 | 2019-04-04 |
Recent Filings
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-10 | ANIP | Grant (A) | +4,357 | $0 | EDGAR |
| 2025-09-04 | ANIP | Sell (S) | −7,292 | -$692.3K | EDGAR |
| 2025-09-03 | ANIP | Notice (144) | −7,292 | -$692.3K | EDGAR |
| 2025-08-20 | ANIP | Notice (144) | −5,421 | -$486.4K | EDGAR |
| 2025-08-20 | ANIP | Sell (S) | −5,421 | -$486.4K | EDGAR |
| 2025-05-27 | ANIP | Grant (A) | +4,336 | $0 | EDGAR |
| 2024-05-23 | ANIP | Grant (A) | +4,410 | $0 | EDGAR |
| 2024-03-06 | ANIP | Sell (S) | −7,000 | -$456.4K | EDGAR |
| 2024-03-04 | ANIP | Notice (144) | −7,000 | -$456.4K | EDGAR |
| 2023-08-15 | ANIP | Sell (S) | −3,000 | -$181.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.